Brokerages Anticipate Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) to Announce -$0.24 Earnings Per Share

Wall Street analysts expect that Processa Pharmaceuticals, Inc. (NASDAQ:PCSAGet Rating) will report earnings per share of ($0.24) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Processa Pharmaceuticals’ earnings. Processa Pharmaceuticals posted earnings of ($0.14) per share in the same quarter last year, which suggests a negative year over year growth rate of 71.4%. The business is expected to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Processa Pharmaceuticals will report full-year earnings of ($1.01) per share for the current financial year. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Processa Pharmaceuticals.

Processa Pharmaceuticals (NASDAQ:PCSAGet Rating) last announced its earnings results on Wednesday, March 30th. The company reported ($0.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.03). During the same period last year, the business posted ($0.90) EPS.

Separately, Zacks Investment Research upgraded shares of Processa Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, March 30th.

Shares of PCSA opened at $3.19 on Monday. Processa Pharmaceuticals has a 12 month low of $2.98 and a 12 month high of $9.37. The firm has a fifty day simple moving average of $3.45 and a 200 day simple moving average of $4.92. The stock has a market capitalization of $50.54 million, a price-to-earnings ratio of -4.31 and a beta of 0.01.

A number of hedge funds have recently made changes to their positions in PCSA. BlackRock Inc. lifted its stake in Processa Pharmaceuticals by 12.9% in the fourth quarter. BlackRock Inc. now owns 30,501 shares of the company’s stock valued at $149,000 after acquiring an additional 3,477 shares during the last quarter. Coastal Bridge Advisors LLC lifted its stake in Processa Pharmaceuticals by 18.2% in the fourth quarter. Coastal Bridge Advisors LLC now owns 32,500 shares of the company’s stock valued at $159,000 after acquiring an additional 5,000 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Processa Pharmaceuticals by 73.5% in the third quarter. Geode Capital Management LLC now owns 64,902 shares of the company’s stock valued at $556,000 after acquiring an additional 27,502 shares during the last quarter. Hedge funds and other institutional investors own 9.00% of the company’s stock.

Processa Pharmaceuticals Company Profile (Get Rating)

Processa Pharmaceuticals, Inc engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its lead product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E.

See Also

Get a free copy of the Zacks research report on Processa Pharmaceuticals (PCSA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Processa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Processa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.